Macrogen opens office in Australia
South Korean biotech company Macrogen has opened an office in New South Wales, with an aim to service clients in Australia and New Zealand.
The local office will offer individualised consultation and facilitate hassle-free samples submissions.
Established in 1997 from the Genome Medical Research Institute of Seoul National University, Macrogen has subsidiaries in US, EU, Japan, Singapore and now in Australia. The company has partnered with 18,000 scientists over 150 countries.
Macrogen's primary business is research and this specialty provides services in sequence analysis (CES, NGS), biochip analysis (microarray), oligo synthesis (oligo), GEM (Genetically Engineered Mouse) and bioinformatics that serve biotechnology and clinical studies. It performs research for governmental agencies, universities and research institutes. It provides patients and healthcare professionals with clinical diagnostic results, offers the general public personal genome studies and uses advanced technologies in the fields of forensics and companion animals.
Clinical diagnostics and personal genome studies are an integral part of precision medicine and that is where Macrogen makes large investments and performs research and development. It is involved in genome testing for cancer, antepartum and rare diseases, and personal genome testing to provide customised diagnostics, treatment and care.
Applications include blood relationship and individual identification gene test service (iD4U) and the gene test service for companion animals (myPETGENE).
Long COVID abnormalities appear to resolve over time
Researchers at UNSW's Kirby Institute have shown that biomarkers in long COVID patients have...
RNA-targeted therapy shows promise for childhood dementia
Scientists have shown that a new RNA-targeted therapy can halt the progression of a specific type...
Parkinson's alters emotion-related bodily sensations
People with Parkinson's disease were found to have significant differences in all bodily...
